Repros Therapeutics (RPRX) Issues Update on Enclomiphene Study vs. Diet and Exercise in Secondary Hypogonadal Men
Go back to Repros Therapeutics (RPRX) Issues Update on Enclomiphene Study vs. Diet and Exercise in Secondary Hypogonadal Men| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 27.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.82 | 52 Week High | $3.48 | |||
| Open | $27.84 | 52 Week Low | $0.80 | |||
| Day High | $27.97 | P/E | N/A | |||
| Day Low | $27.21 | EPS | $-1.54 | |||
| Volume | 4,682,025 | |||||
